A health plan's integration of molecular diagnostics and the impact on treatment pathways for quality care.

Managed care (Langhorne, Pa.)

Volumn 17, Issue 7 Suppl 7, 2008, Pages

  Wong, Winston ^a  

^a Pharmacy Management   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLUE CROSS BLUE SHIELD; BREAST TUMOR; CANCER STAGING; CLINICAL PATHWAY; COST CONTROL; ECONOMICS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; HEALTH INSURANCE; HEALTH SERVICES RESEARCH; HUMAN; ONCOLOGY; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE; TREATMENT OUTCOME; UNITED STATES;

BLUE CROSS BLUE SHIELD INSURANCE PLANS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST CONTROL; CRITICAL PATHWAYS; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; GENOMICS; HUMANS; MANAGED CARE PROGRAMS; MEDICAL ONCOLOGY; MID-ATLANTIC REGION; NEOPLASM STAGING; ORGANIZATIONAL CASE STUDIES; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 58949097409     PISSN: 10623388     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)